Strides Pharma likely to launch affordable insulin from Stelis stable

Strides Pharma Science could get access to the insulin market as Stelis Biopharma, in which it is in the process of acquiring a controlling stake, is building an integrated insulin and insulin analogue platform with proprietary technology.

The Bengaluru-headquartered company believes Stelis could be a disruptor in insulin accessibility and affordability. Strides may commercialise the insulin coming out of the R&D facility in future but has not set a timeline for the same.

A World Health Organization (WHO) report says there are 73 million people suffering from diabetes in India and the prices of insulin in the country have gone up by